Overall impact
B (69)

Commentary

Isoray is a strong overall performer. With a 'B' rating of 68.9 for overall impact (80th percentile compared to all companies), Isoray ranks 37th out of 103 industry peers, behind MyMD Pharmaceuticals, Alphatec, electroCore and 33 others, and ahead of Waters, Biolase, Biomerica and 63 others. On top material causes for Isoray's industry (Healthcare Equipment), Isoray performs well in Conflict Free Mineral Production (96.0 score), Access to Affordable Healthcare (95.5), Child and Maternal Health (83.6) and 4 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (22.0 score).
Impact
Cause ISR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
66
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Wa, United States
Share classes
ISR
Description
Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Material causes
Ethos considers the following causes material for Isoray, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.